Drug Trial Radar · NCT06844799
A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Feb 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
720
Planned (sponsor's estimate)
Start
Jun 10, 2025
Primary completion
Mar 31, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Hansoh BioMedical R&D CompanyIndustry
- Sponsor type
- Industry
- First posted
- Feb 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy and safety of HS-20137 in the treatment of participants with moderate to severe plaque psoriasis.
Conditions
- Moderate-to-severe Plaque Psoriasis
Interventions
HS-20137Drug
HS-20137 200mg injection at week 0, 4, 8 and then every 8 or 12 weeks.
Placebo&HS-20137Drug
Placebo injection at week 0, 4, 8, and then HS-20137 200mg injection at week 16, 20, 24, and every 8 or 12 weeks thereafter
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Psoriasis Area and Severity Index (PASI) Score of 90 Percent or AboveTime frame: At week 16
- Physician Global Assessment (PGA) score of 0/1Time frame: At week 16
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.